Asialoglycoprotein Receptor 1 (Protein | Antibody | cDNA Clone | ELISA Kit)

All Asialoglycoprotein Receptor 1 reagents are produced in house and quality controlled, including 11 Asialoglycoprotein Receptor 1 Antibody, 2 Asialoglycoprotein Receptor 1 ELISA, 38 Asialoglycoprotein Receptor 1 Gene, 3 Asialoglycoprotein Receptor 1 IP Kit, 2 Asialoglycoprotein Receptor 1 Lysate, 4 Asialoglycoprotein Receptor 1 Protein, 2 Asialoglycoprotein Receptor 1 qPCR. All Asialoglycoprotein Receptor 1 reagents are ready to use.

All Asialoglycoprotein Receptor 1 Reagents

More Product Popular With Customers

Asialoglycoprotein Receptor 1 Related Research Area

Asialoglycoprotein Receptor 1 Background

The asialoglycoprotein receptor (ASGPR), an endocytotic cell surface receptor expressed by hepatocytes, is triggered by triantennary binding to galactose residues of macromolecules such as asialoorosomucoid (ASOR). ASGPR belongs to the long-form subfamily of the C-type/Ca2+ dependent lectin family. It is a complex of two noncovalently-linked and highly homologous subunits, a major 42 kDa glycoprotein ASGPR1(MHL-1) and a minor 51 kDa glycoprotein ASGR2 (MHL-2). ASGPR1 is synthesized as a type II transmembrane protein that contains a cytosolic N-terminal domain, a single transmembrane segment, and an extracellular domain which contains two important structural regions. The first is a stalk domain that contributes to noncovalent oligomerization, and the second is a Ca2+-dependent carbohydrate binding domain at the very C-terminus that is unusually stabilized by three ions. The research regarded that ASGPR1 could be targeted for anti- hepatitis B virus (HBV) drug development.

Asialoglycoprotein Receptor 1 References

  • Yang J, et al. (2006) Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication. J Viral Hepat. 13(3): 158-65.
  • Li Y, et al. (2008) Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv. 5(4): 299-302.
彩票大奖得主捐赠 金蟾捕鱼有什么技巧吗 欢乐斗牛棋牌下载手 专家免费推荐股票 欢乐棋牌下载 河南体彩11选5开奖结果 广东闲来麻将 股市行情今日大盘指 广东福彩快乐十分开奖 王者捕鱼官方下载 温州麻将打法